Advertisement
AXON vs XERS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and XERS is a Hold.
AXON in -1.45% downward trend, falling for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AXON declined for three days, in 201 of 288 cases, the price declined further within the following month. The odds of a continued downward trend are 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for AXON entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for AXON's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 56 cases where AXON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 27 of 38 cases over the following month. The odds of a continued upward trend are 71%.
Following a +4.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 276 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.629) is normal, around the industry mean (4.941). AXON has a moderately high P/E Ratio (158.012) as compared to the industry average of (17.156). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
XERS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for XERS turned positive on September 21, 2026. Looking at past instances where XERS's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on XERS as a result. In 72 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
XERS moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for XERS crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +5.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in 219 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for XERS moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 38 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 65 cases where XERS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
XERS broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XERS entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XERS's P/B Ratio (-193.109) is very low in comparison to the industry average of (10.234). P/E Ratio (-103.100) is within average values for comparable stocks, (-6.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (4.196) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
AXON | XERS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 72 | 25 | |
SMR RATING 1..100 | 81 | 100 | |
PRICE GROWTH RATING 1..100 | 64 | 36 | |
P/E GROWTH RATING 1..100 | 41 | 99 | |
SEASONALITY SCORE 1..100 | 85 | 37 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XERS's Valuation (1) in the Pharmaceuticals Major industry is significantly better than the same rating for AXON (92) in the Biotechnology industry. This means that XERS’s stock grew significantly faster than AXON’s over the last 12 months.
XERS's Profit vs Risk Rating (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for AXON (72) in the Biotechnology industry. This means that XERS’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to XERS’s over the last 12 months.
XERS's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as AXON (64) in the Biotechnology industry. This means that XERS’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for XERS (99) in the Pharmaceuticals Major industry. This means that AXON’s stock grew somewhat faster than XERS’s over the last 12 months.
| AXON | XERS | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 89% | 4 days ago 84% |
| Stochastic ODDS (%) | 4 days ago 84% | 4 days ago 72% |
| Momentum ODDS (%) | N/A | 4 days ago 86% |
| MACD ODDS (%) | 4 days ago 71% | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 69% | 4 days ago 73% |
| TrendMonth ODDS (%) | 4 days ago 71% | 4 days ago 86% |
| Advances ODDS (%) | 11 days ago 74% | 4 days ago 86% |
| Declines ODDS (%) | 6 days ago 70% | 6 days ago 77% |
| BollingerBands ODDS (%) | 4 days ago 79% | 4 days ago 75% |
| Aroon ODDS (%) | 4 days ago 58% | 4 days ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while XERS’s FA Score has 2 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- XERS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while XERS’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 2 bearish.
- XERS’s TA Score: 5 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -7.71% price change this week, while XERS (@Pharmaceuticals: Generic) price change was -1.62% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -4.71%. For the same industry, the average monthly price growth was -13.62%, and the average quarterly price growth was -19.39%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.72%. For the same industry, the average monthly price growth was -7.71%, and the average quarterly price growth was +7.81%.
Reported Earning Dates
AXON is expected to report earnings on Nov 10, 2026.
XERS is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Aerospace & Defense (-4.71% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Pharmaceuticals: Generic (-4.72% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
XERS and
Correlation & Price change
A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.
| Ticker / NAME | Correlation To XERS | 1D Price Change % | ||
|---|---|---|---|---|
| XERS | 100% | +2.38% | ||
| MIRM - XERS | 45% Loosely correlated | -2.73% | ||
| KROS - XERS | 38% Loosely correlated | -3.96% | ||
| AXON - XERS | 37% Loosely correlated | -6.45% | ||
| REPL - XERS | 36% Loosely correlated | -7.57% | ||
| BNTC - XERS | 36% Loosely correlated | -4.14% | ||
More | ||||